Provided by Tiger Fintech (Singapore) Pte. Ltd.

Annovis Bio, Inc.

3.21
+0.16005.25%
Post-market: 3.300.0850+2.65%19:59 EDT
Volume:633.88K
Turnover:2.05M
Market Cap:62.55M
PE:-1.53
High:3.40
Open:3.09
Low:3.03
Close:3.05
Loading ...

Annovis to Attend AD/PD™ 2025 with Extensive Scientific Program

GlobeNewswire
·
25 Mar

Reported Friday, Annovis Bio Q4 2024 GAAP EPS $(0.43) Misses $(0.40) Estimate, Cash $10.6M

Benzinga
·
24 Mar

Annovis Bio reports Q4 EPS (43c) vs. ($2.24) last year

TIPRANKS
·
22 Mar

Annovis Provides Corporate Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results

THOMSON REUTERS
·
22 Mar

Press Release: Annovis Provides Corporate Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results

Dow Jones
·
22 Mar

Annovis Joins Experts at Drug Development Summit to Redefine Parkinson's Treatment

GlobeNewswire
·
11 Mar

Annovis to Host Patients’ Live Forum on February 27, 2025

GlobeNewswire
·
19 Feb

Annovis Bio Cut to Hold From Buy by D. Boral Capital

Dow Jones
·
10 Feb

Annovis to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference

GlobeNewswire
·
07 Feb

Annovis Bio announces first patients entered Phase 3 study of buntanetap

TipRanks
·
06 Feb

Annovis Bio Enrolls First Patients in Phase 3 Trial of Buntanetap for Early Alzheimer's Disease

MT Newswires Live
·
06 Feb

Annovis Bio Launches Phase 3 Alzheimer’s Study

TIPRANKS
·
05 Feb

Annovis Announces First Patients Entered Into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer’s Disease

THOMSON REUTERS
·
05 Feb

Annovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer’s Disease

GlobeNewswire
·
05 Feb

BRIEF-Annovis Bio Announces Closing Of $21 Million Public Offering

Reuters
·
05 Feb

Annovis Bio, Inc. Announces Closing of $21 Million Public Offering

THOMSON REUTERS
·
05 Feb

Annovis Bio Inc - Proceeds to Fund Phase 3 Study of Buntanetap for Alzheimer's

THOMSON REUTERS
·
05 Feb

Sector Update: Health Care Stocks Higher Monday Afternoon

MT Newswires Live
·
04 Feb

Annovis Bio Prices $21 Million Public Offering; Shares Fall Sharply

MT Newswires Live
·
04 Feb

Annovis Bio falls -25.6%

TIPRANKS
·
03 Feb